Legend Capital

TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer.

DK Medtech is a medical technology company based in Suzhou, China, specializing in the development and production of balloon catheter medical devices. Founded in 2015, the company has positioned itself as a leader in the medical device industry, focusing on innovative solutions to address complex healthcare challenges. Through its commitment to excellence, DK Medtech aims to improve patient outcomes and enhance the quality of healthcare.

ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

XSKY Data Technology, based in Beijing, specializes in software-defined infrastructure products and services. It offers a range of storage solutions, including XCBS (cloud), XEBS (block), XEUS (unified), XEOS (object), and XEDP (unified data platform), catering to diverse sectors such as finance, telecom, energy, and government. XSKY is a significant contributor to the open-source Ceph storage system, ranking top 3 globally. It partners with leading tech companies like Intel and Samsung, providing scalable, cost-effective storage solutions tailored for enterprise needs.

Founded in 2007, MicuRx Pharmaceuticals discovers and develops novel antibiotics to combat drug-resistant bacterial infections. Its pipeline includes MRX-I, an oral antibiotic for gram-positive infections, MRX-IV for intravenous use, MRX-V for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company operates under a hybrid U.S./China business model.

ZKH is a digital service platform for industrial products that offers comprehensive supply chain solutions based on an E-commerce platform, digital tools, and intelligent service. Its platform offers a comprehensive selection of industrial accessories, consumables, general equipment, and spare parts. There are 28 product lines and over 4 million SKUs available, including PPE, hand tools, metal processing, fasteners, instruments, chemicals, and so on.

Novast is a multinational pharmaceutical company focused on the research, development, and manufacture of value-added and complex dosage forms, including controlled-release and other advanced drug-delivery systems. With operations in China and the United States, it partners with pharmaceutical and biotechnology companies to develop and commercialize products for regulated markets, providing product development services and leveraging proprietary technologies. The company emphasizes designing formulations for challenging APIs and global markets, supported by cGMP manufacturing capabilities and quality systems. It also engages in contract research, development, and quality control to support clients in achieving regulatory approval and efficient market access. Through its drug-delivery platforms and comprehensive development capabilities, Novast aims to improve access to affordable, high-quality medications while expanding its international footprint.

Innovent Biologics is a China-based biopharmaceutical company that discovers, develops, manufactures, and commercializes monoclonal antibodies. It operates a platform for antibody therapeutics across oncology, ophthalmology, immunology, and metabolic diseases, with Tyvyt (sintilimab) as its core asset, a PD-1 inhibitor used in first-line and other cancer indications. The company develops a broad pipeline including biosimilars and novel antibodies and provides distribution, consulting, and R&D services. It maintains strategic collaborations with global partners, including a co-development arrangement with MD Anderson Cancer Center and an alliance with Eli Lilly for TYVYT, and has more than 30 collaborations with major pharmaceutical companies. Innovent is listed on the Hong Kong Exchange and maintains manufacturing and development capabilities in China with a growing portfolio of oncology and non-oncology products marketed domestically and internationally.